01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
14:23 , Mar 20, 2019 |  BC Extra  |  Financial News

Follow-on roundup: Dermira, resTORbio, NanoString

Dermira raised $130 million in an upsized offering that followed closely after its eczema readout this week, while resTORbio and NanoString also priced follow-ons late Tuesday. Dermira Inc. (NASDAQ:DERM) sold 9.8 million shares at $13.25,...
00:27 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Flipping the switch in immuno-oncology

Tumor myeloid cells are emerging as prime candidates for filling a hole in the immuno-oncology tool box, offering targets that can simultaneously release the brakes and rev up the gas in the immune system. As...
03:38 , Jan 11, 2019 |  BC Innovations  |  Product R&D

PureTech turns inward

After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift...
17:03 , Jan 4, 2019 |  BC Week In Review  |  Financial News

China's Antengene raises $120M series B round

Antengene Corp. (Shanghai, China) completed a $120 million series B round on Jan. 2 to fund development of its two lead cancer compounds, selinexor and ATG-008. Boyu Capital and FountainVest led the round, with participation...
01:05 , Jan 4, 2019 |  BC Week In Review  |  Company News

Xynomic returns to Boehringer for second cancer candidate

Xynomic Pharmaceuticals (Dover, Del.) gained exclusive, worldwide rights to BI 860585 from Boehringer Ingelheim GmbH (Ingelheim, Germany). Response from Xynomic Business Development Manager Angela Fung told BioCentury that Xynomic will pay Boehringer up to $800...
21:56 , Jan 2, 2019 |  BC Extra  |  Financial News

China's Antengene raises $120M series B round

Antengene Corp. (Shanghai, China) completed a $120 million series B round to fund development of its two lead cancer compounds, selinexor and ATG-008. Boyu Capital and FountainVest led the round, with participation by Celgene Corp....
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
20:11 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Heart transplant rejection Mouse studies suggest APOA/phospholipid-based nanoparticles loaded with rapamycin or a TRAF6 inhibitor could help prevent heart transplant rejection. The nanoparticles consist of APOA and natural phospholipid components of HDL cholesterol isolated...